arrow
J

Jibran Ahmed

national institute of health
H指数:10
被引数:472

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Phase I trial of the combination of bortezomib and clofarabine in adults with refractory tumors

I期临床试验:评估硼替佐米与克洛拉拉滨联合方案在难治性肿瘤成人患者中的应用

2026-03-140
OAAI
ASO Visual Abstract: Efficacy of Bidirectional Paclitaxel Plus Capecitabine or Nilotinib for Peritoneal Carcinomatosis: A Single-Institution Analysis of Two Phase II Clinical Trials

ASO视觉摘要:双向紫杉醇联合卡培他滨或尼罗替尼治疗腹膜癌病的疗效:一项单机构两项II期临床试验的分析

2026-02-070
PRE
Efficacy of Bidirectional Paclitaxel plus Capecitabine or Nilotinib for Peritoneal Carcinomatosis: A Single Institution Analysis of Two Phase II Clinical Trials
2026-01-160
OAAI
A phase I/II trial of avelumab combinations with ivuxolimab, utomilumab, and radiation therapy in patients with advanced gastrointestinal malignancies

一项avelumab联合ivuxolimab、utomilumab和放射治疗的I/II期临床试验,用于治疗晚期胃肠道恶性肿瘤患者

2025-03-010
PRE
A phase I study of temsirolimus in combination with metformin in patients with advanced or recurrent endometrial cancer

一项关于temsirolimus联合metformin治疗晚期或复发性子宫内膜癌的I期研究

2025-02-011
PRE
Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies

avelumab联合utomilumab (4-1BB激动剂),PF-04518600 (OX40激动剂) 或放疗在晚期妇科恶性肿瘤患者中的1/2期试验

CANCER
IF5.1
2023-10-216
PRE